FindTrial
Sign In

To evaluate efficacy of image-guided intensity modulated radiotherapy using fiducial gold markers for localized advanced prostate cancer

To evaluate efficacy of image-guided intensity modulated radiotherapy using fiducial gold markers for localized advanced prostate cancer - To evaluate efficacy of image-guided IMRT using fiducial gold markers for prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006612
Enrollment
60
Registered
2011-11-01
Start date
2011-11-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Patients are treated with image-guided IMRT (76-80Gy/38-40fx.) using fiducial gold markers in the prostate.

Sponsors

Tohoku University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) High-risk prostate cancer with cT1-3bN0M0 confirmed by histological diagnosis and MRI or bone scintigraphy 2) Patient should receive MRI examination before treatment. 3) ECOG PS 0-1 4) Patients must sign informed consent form prior to registration

Exclusion criteria

Exclusion criteria: 1) Prior pelvic radiotherapy 2) Small cell carcinoma 3) cT4, exist of metastasis 4) Prior prostatectomy 5) Concurrent invasive cancers or collagen disease 6) PSA failure following hormonal therapy 7) If the attending physician judges the case inappropriate.

Design outcomes

Primary

MeasureTime frame
Biochemical relapse free survival Cause-specific survival Overall survival Toxicity—

Countries

Japan

Contacts

Public ContactKen Takeda

Health Sciences, Tohoku University Graduate School of Medicine Department of Therapeutic Radiology

ken.takeda.a3@tohoku.ac.jp022-717-7909

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026